+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy



Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy



Journal of Cardiovascular Pharmacology and Therapeutics 14(3): 176-179



Of 209 patients with heart failure treated with combined cardiac resynchronization therapy and implantable cardioverter-defibrillator therapy, appropriate cardioverter-defibrillator shocks occurred at 34-month follow-up in 22 of 121 patients (18%) on statins and in 30 of 88 patients (34%) not on statins (P = .009). Deaths occurred in 3 of 121 patients (2%) on statins and in 9 of 88 patients (10%) not on statins (P = .017). Stepwise Cox regression analysis showed that significant independent prognostic factors for appropriate shocks were use of statins (risk ratio = 0.46), smoking (risk ratio = 3.5), and diabetes (risk ratio = 0.34). Significant independent prognostic factors for the time to mortality were use of statins (risk ratio = 0.05), use of digoxin (risk ratio = 4.2), systemic hypertension (risk ratio = 14.2), diabetes (risk ratio = 4.3), and left ventricular ejection fraction (risk ratio = 1.1).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055912305

Download citation: RISBibTeXText

PMID: 19617418

DOI: 10.1177/1074248409340157


Related references

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy. Journal of Cardiovascular Pharmacology and Therapeutics 15(1): 37-40, 2010

Statins Reduce Appropriate Cardioverter-Defibrillator Shocks And Mortality In Patients With Heart Failure And Combined Cardiac Resynchronization Therapy And Cardioverter-Defibrillators. Chest 136(4): 99S-1-99S-2, 2009

Incidence Of Appropriate Cardioverter-Defibrillator Shocks And Of Mortality In Patients With Heart Failure Treated With Combined Cardiac Resynchronization Plus Cardioverter-Defibrillator Therapy Versus Cardioverter-Defibrillator Therapy. Chest 136(4): 100S-1-100S-2, 2009

The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). Journal of the American College of Cardiology 63(12): 1190-1197, 2014

Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. American Journal of Cardiology 105(9): 1336-1338, 2010

Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT). American Journal of Cardiology 115(10): 1423-1427, 2015

Multiple shocks after upgrade of an implantable cardioverter-defibrillator to a cardiac resynchronization therapy-defibrillator device. Cardiology Journal 16(5): 473-476, 2009

Yield of left ventricular dyssynchrony by gated SPECT MPI in patients with heart failure prior to implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator: Characteristics and prediction of cardiac outcome. Journal of Nuclear Cardiology 24(1): 122-129, 2015

Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. European Journal of Heart Failure 16(12): 1323-1330, 2015

The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. Europace 15(7): 992-1001, 2014

Cardiac resynchronization and implantable cardioverter defibrillator therapy: preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry. Pacing and Clinical Electrophysiology 26(1 Pt 2): 148-151, 2003

Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. JAMA Cardiology 2(5): 561-565, 2017

Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Annals of Internal Medicine 163(6): 417-426, 2015

Diabetes Mellitus and Outcomes of Cardiac Resynchronization With Implantable Cardioverter-Defibrillator Therapy in Older Patients With Heart Failure. Circulation. Arrhythmia and Electrophysiology 9(8), 2017

Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure. Current Opinion in Cardiology 19(3): 264-269, 2004